New York, June 4, 2026, 14:05 EDT
Tango Therapeutics shares traded up 1.8% at $21.86 during Thursday afternoon hours. The cancer-drug maker stayed close to its highs after a new filing disclosed the company’s research chief had sold stock using a preset trading plan. The SPDR S&P Biotech ETF climbed 2.6%.
Tango is a popular small-cap biotech trade, and the latest move has some impact. Shares are up around 149% this year, according to MarketBeat. Every insider filing and update on the company’s main cancer program has some effect as a result.
Tango’s president of research and development, Adam Crystal, M.D., Ph.D., exercised options for 27,000 shares at $5.20 apiece on June 1, then sold all 27,000 shares in two trades at weighted averages of $22.252 and $23.0558, according to the Form 4. The sales happened under a Rule 10b5-1 trading plan, which allows insiders to set up trades ahead of time.
Crystal sold roughly $617,571 worth of stock before transaction costs, according to the filing’s weighted average prices. The filing also showed Crystal owns 115,743 shares and 341,040 options after the trades.
Insider sales aren’t always a signal about the outlook for a company. But the timing here stands out. Tango’s valuation depends less now on earnings results and more on whether its vopimetostat program can deliver clinical data to justify a bigger trial.
Vopimetostat is the lead PRMT5 inhibitor at Tango. PRMT5 is tied to cell growth, and Tango is looking at whether blocking it works in cancers that have MTAP deletion, which is a type of missing gene found in some tumors. In May, the company said patient enrollment was “robust” in an ongoing Phase 1/2 trial testing vopimetostat with Revolution Medicines’ RAS(ON) inhibitors. Initial safety and efficacy data are on track for 2026. GlobeNewswire
Chief Executive Malte Peters said in the update that Tango was “focused on the clinical and regulatory work” needed to begin a pivotal study for MTAP-deleted pancreatic cancer. The pivotal study is a late-stage trial meant to back a regulatory filing. GlobeNewswire
Tango’s field isn’t wide. Erasca is teaming up with Tango for a Phase 1/2 study of ERAS-0015 plus vopimetostat in MTAP-deleted pancreatic cancer or MTAP-deleted, RAS-mutant non-small cell lung cancer. Tango is the trial sponsor while Erasca provides its drug for free.
Revolution Medicines had another update in May. The company said its RAS(ON) inhibitors are now in combination studies with Tango’s vopimetostat. Bristol Myers Squibb is in a separate trial combining daraxonrasib with its PRMT5 inhibitor, navlimetostat, in pancreatic cancer patients with both RAS mutation and MTAP deletion.
Erasca rose 1.3% in the afternoon session, with Revolution Medicines up 0.7%. Both moves tracked the firmer biotech sector.
Andrew Berens at Leerink Partners said in March that the push into PRMT5-plus-RAS programs pointed to “early signals are favorable,” according to Investor’s Business Daily. That sums up the bull view: more combinations, more shots on goal, and the data isn’t out yet. Investors
The risk is obvious. Tango doesn’t have any approved products. Clinical testing can still fail after promising early data. The company’s annual filing said drug development is speculative, it hasn’t done big pivotal trials, and interim or early data might not match final results.
Right now, this is a data trade. The next real check isn’t the Form 4. It’s if the 2026 vopimetostat results hold up for the run the stock’s had.
